← Back to Screener
SiNtx Technologies, Inc. Common Stock (SINT)
Price$2.78
Favorite Metrics
Price vs S&P 500 (26W)-43.77%
Price vs S&P 500 (4W)-1.46%
Market Capitalization$11.09M
All Metrics
Book Value / Share (Quarterly)$1.13
P/TBV (Annual)1.21x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)68.26%
Cash Flow / Share (Quarterly)$-2.11
Price vs S&P 500 (YTD)-34.45%
Gross Margin (TTM)52.05%
Net Profit Margin (TTM)-775.12%
EPS (TTM)$-4.66
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-4.66
Revenue Growth (5Y)33.18%
EPS (Annual)$-14.87
ROI (Annual)-280.79%
Gross Margin (Annual)71.91%
Net Profit Margin (5Y Avg)-837.39%
Cash / Share (Quarterly)$1.73
Revenue Growth QoQ (YoY)-73.97%
ROA (Last FY)-117.11%
Revenue Growth TTM (YoY)-60.89%
EBITD / Share (TTM)$-4.39
ROE (5Y Avg)-133.94%
Operating Margin (TTM)-798.03%
Cash Flow / Share (Annual)$-6.95
P/B Ratio2.73x
P/B Ratio (Quarterly)3.61x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)3.86x
Net Interest Coverage (TTM)-10.10x
ROA (TTM)-95.06%
EPS Incl Extra (Annual)$-14.87
Current Ratio (Annual)2.41x
Quick Ratio (Quarterly)1.47x
3-Month Avg Trading Volume0.04M
52-Week Price Return55.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.08
P/S Ratio (Annual)3.84x
Asset Turnover (Annual)0.31x
52-Week High$6.78
Operating Margin (5Y Avg)-968.16%
EPS Excl Extra (Annual)$-14.87
CapEx CAGR (5Y)36.24%
Tangible BV CAGR (5Y)-5.56%
26-Week Price Return-35.02%
Quick Ratio (Annual)1.92x
13-Week Price Return-27.10%
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)1.70x
Enterprise Value$4.896
Asset Turnover (TTM)0.12x
Book Value / Share Growth (5Y)-71.28%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.17x
Pretax Margin (Annual)-381.85%
Cash / Share (Annual)$2.68
3-Month Return Std Dev51.86%
Gross Margin (5Y Avg)54.21%
Net Income / Employee (TTM)$-0
ROE (Last FY)-283.10%
Net Interest Coverage (Annual)-29.66x
EPS Basic Excl Extra (Annual)$-14.87
Receivables Turnover (TTM)5.52x
Total Debt / Equity (Quarterly)0.01x
EPS Incl Extra (TTM)$-4.66
Receivables Turnover (Annual)6.55x
ROI (TTM)-214.31%
P/S Ratio (TTM)8.73x
Pretax Margin (5Y Avg)-837.39%
Revenue / Share (Annual)$3.89
Tangible BV / Share (Annual)$2.89
Price vs S&P 500 (52W)20.40%
Year-to-Date Return-30.31%
5-Day Price Return-6.27%
EPS Normalized (Annual)$-14.87
ROA (5Y Avg)-62.58%
Net Profit Margin (Annual)-381.85%
Month-to-Date Return7.48%
Cash Flow / Share (TTM)$-4.95
EBITD / Share (Annual)$-18.53
Operating Margin (Annual)-486.56%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-129.41%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.66
P/TBV (Quarterly)3.74x
P/B Ratio (Annual)1.21x
Inventory Turnover (TTM)1.34x
Pretax Margin (TTM)-775.12%
Book Value / Share (Annual)$2.90
Price vs S&P 500 (13W)-29.97%
Beta0.80x
Revenue / Share (TTM)$0.43
ROE (TTM)-218.25%
52-Week Low$1.71
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
SINTSiNtx Technologies, Inc. Common Stock | 8.73x | 33.18% | 52.05% | -798.03% | $2.78 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
SINTX Technologies Inc manufactures silicon nitride ceramics for biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, and antipathogenic with strong bone affinity characteristics. The company's silicon nitride spinal implants have achieved clinical adoption in the US, Europe, Brazil, and Taiwan.